MARKET

AGTC

AGTC

AGTC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.920
-0.160
-5.19%
Closed 16:00 10/21 EDT
OPEN
3.010
PREV CLOSE
3.080
HIGH
3.130
LOW
2.810
VOLUME
126.44K
TURNOVER
--
52 WEEK HIGH
7.48
52 WEEK LOW
2.260
MARKET CAP
53.20M
P/E (TTM)
-25.2595
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AGTC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AGTC News

  • 33 Stocks Moving In Monday's Mid-Day Session
  • Benzinga.16h ago
  • AGTC Presents Data Demonstrating Efficiency of its AAV Vectors for Ocular Gene Therapy Even in the Presence of Anti-AAV Antibodies
  • GlobeNewswire.21h ago
  • Applied Genetic Technologies (AGTC) Investor Presentation - Slideshow
  • Seeking Alpha - Article.10/03 21:45
  • 25 Healthcare Stocks Moving In Wednesday's Pre-Market Session
  • Benzinga.10/02 12:54

More

Industry

Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+0.40%

Hot Stocks

Name
Price
%Change

About AGTC

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
More

Webull offers Applied Genetic Technologies Corp (AGTC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.